Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Hantz Financial Services Inc.

Hantz Financial Services Inc. increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3,368.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,146 shares of the biopharmaceutical company’s stock after buying an additional 12,767 shares during the quarter. Hantz Financial Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,995,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $30,000. ORG Partners LLC grew its stake in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 33 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $37,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president directly owned 29,728 shares of the company’s stock, valued at $10,787,399.36. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares in the company, valued at $20,852,324.55. This trade represents a 4.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 56,955 shares of company stock valued at $24,072,733. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ALNY shares. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Bank of America reduced their price objective on Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, HC Wainwright decreased their price target on Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating for the company in a report on Friday, January 30th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $477.13.

Alnylam Pharmaceuticals Trading Up 0.0%

NASDAQ:ALNY opened at $351.96 on Thursday. The stock has a market cap of $46.50 billion, a price-to-earnings ratio of 1,466.50 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The business’s 50-day simple moving average is $394.28 and its 200 day simple moving average is $424.94.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.